Pricing and reimbursement of in-patent drugs in seven European countries: A comparative analysis
- 31 August 2007
- journal article
- research article
- Published by Elsevier BV in Health Policy
- Vol. 82 (3), 330-339
- https://doi.org/10.1016/j.healthpol.2006.11.004
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Reference drug programs: Effectiveness and policy implicationsHealth Policy, 2007
- The costs and benefits of regulations for reimbursement of new drugsHealth Policy, 2006
- Disappointing biotechBMJ, 2005
- Health care reform in BelgiumHealth Economics, 2005
- Pharmaceutical policy in Italy: towards a structural change?Health Policy, 2005
- Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdleBMJ, 2004
- The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990sHealth Economics, 2004
- Examining the link between price regulation and pharmaceutical R&D investmentHealth Economics, 2004
- Pharmaceutical pricing and reimbursement in SpainThe European Journal of Health Economics, 2001
- Developing Guidance for Budget Impact AnalysisPharmacoEconomics, 2001